Russian Sputnik V Covid-19 vaccine (Pic Via Sputnik V website)The subject expert committee (SEC) of the Central Drugs Standard Control Organisation(CDSCO), India's drug regulator, has deferred its decision on whether to recommend the Russian Sputnik V Covid-19 vaccine for emergency use, reports Livemint.
Hyderabad based pharmaceutical major Dr Reddy's Laboratories which had applied for the EUA for Sputnik V has been asked to provide more data to the SEC before a decision can be taken on the EUA recommendation.
The SEC is said to have asked the pharmaceutical giant to provide the fact sheet for the vaccine along with details on stability, as a variant of the vaccine needs to be stored at a temperature of -18 degree Celsius.
It should be noted that Dr Reddy's has a pact with the vaccine's co-developer Russian Direct Investment Fund (RDIF) for carrying out the clinical trials, and to distribute the vaccine in the country subject to authorisation. The vaccine has claimed a high interim efficacy of 91.6 per cent.
Meanwhile, RDIF has also signed pacts with four other Indian companies for manufacturing a total of 750 million doses.
An Appeal...
Dear Reader,
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.